Literature DB >> 21486624

Combined liver kidney transplantation: critical analysis of a single-center experience.

B Cimsit1, M Schilsky, M Moini, K Cartiera, A Arvelakis, S Kulkarni, R Formica, C Caldwell, T Taddei, W Asch, S Emre.   

Abstract

Combined liver kidney transplantation (LKT) can be successfully performed on patients with liver and renal failure; however, outcomes are inferior to liver transplantation alone (OLT). Our aim was to determine the indications for and outcome of LKT and whether patients with longer wait times required more frequent LKT versus OLT alone. We included 18/93 adults who underwent LKT from August 2007 to August 2010 for hepatitis C virus (HCV, n = 7), alcohol (n = 5), nonalcoholic steatohepatitis (n = 2), primary biliary sclerosis, polycystic kidney disease with liver involvement, hepatic adenomatosis, and ischemic hepatitis. Eleven were originally listed for LKT and 7 required listing for-kidney transplantation while awaiting OLT. Eight were on dialysis when first listed and 10 had a low glomerular filtration rate or known kidney disease. The mean calculated Model for End-Stage Liver Disease (MELD) score for LKT was 31.2 ± 3.54. Seven had hepatocellular carcinoma in explants. Two patients had acute cellular kidney rejection that responded to treatment. Recurrence of HCV was documented in 5 patients within 6 months of LKT; 2/5 received HCV therapy (interferon and ribavirin) without renal allograft rejection. One-year liver graft/patient survival was 94% after LKT. One patient died at 6 months post LKT due to severe HCV recurrence. Last mean serum creatinine level was 1.35 ± 0.28 mg/dL for LKT patients. LKT is a safe procedure with favorable outcomes even in patients with a high MELD score. Transplantation of patients with a high MELD score due to regional variations in organ allocation results in additional use of kidneys by OLT patients. Improved organ allocation algorithms in OLT would help to reduce combined transplants, sparing more kidneys.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21486624     DOI: 10.1016/j.transproceed.2011.02.033

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  A case of a maintenance hemodialysis patient with autosomal dominant polycystic kidney disease who underwent living donor liver transplantation alone due to refractory liver cyst infection.

Authors:  Taro Akihisa; Ayami Ino; Hiroto Egawa; Yoshihito Kotera; Shunichi Ariizumi; Akiko Oomori; Shingo Yamashita; Yusuke Yamamoto; Ken Tsuchiya; Masakazu Yamamoto; Kosaku Nitta; Toshio Mochizuki
Journal:  CEN Case Rep       Date:  2018-06-28

2.  Treatment of Hepatic Adenomatosis.

Authors:  Claire Meyer; Mauricio Lisker-Melman
Journal:  Curr Hepatol Rep       Date:  2015-05-02

3.  The Value of CT Angiography Based on Intelligent Segmentation Algorithm for Survival of Hemodialysis Patients.

Authors:  Wei Luo; Ruidong Zhang; Da He; Zhenyi Sun; Yunlong Zhou; Li Cheng; Hongbo Li
Journal:  Comput Math Methods Med       Date:  2022-01-19       Impact factor: 2.238

4.  Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis.

Authors:  Fang Wei; Junying Liu; Fen Liu; Huaidong Hu; Hong Ren; Peng Hu
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

5.  Long-Term Outcomes of Simultaneous Liver-Kidney Transplant Patients with Hepatitis B Compared to with Liver Transplant Alone.

Authors:  Hao Li; Ming-Qi Fan; Tong-Yi Men; Yun-Peng Wang; Tong-Hai Xing; Jun-Wei Fan; Zhi-Hai Peng; Lin Zhong
Journal:  Med Sci Monit       Date:  2016-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.